A novel mannoside-glycocluster adjuvant: Compared in vitro to CpG ODN and MPL and tested in vivo in mouse asthma model - UTU Research Portal

A1 Refereed original research article in a scientific journal

A novel mannoside-glycocluster adjuvant: Compared in vitro to CpG ODN and MPL and tested in vivo in mouse asthma model

Authors: Makinen K, Mukherjee C, Leino M, Panchadhayee R, Lehto M, Wolff H, Alenius H, Leino R, Savolainen J

Publisher: ELSEVIER DOYMA SL

Publication year: 2016

Journal: Allergologia et Immunopathologia

Journal name in source: ALLERGOLOGIA ET IMMUNOPATHOLOGIA

Journal acronym: ALLERGOL IMMUNOPATH

Volume: 44

Issue: 1

First page : 9

Last page: 17

Number of pages: 9

ISSN: 0301-0546

DOI: https://doi.org/10.1016/j.aller.2015.04.008(external)

Abstract

Conclusions: TADM suppresses the birch allergen induced Th2-type cytokine responses in allergic subjects more efficiently than the two other adjuvants, MPL and CpG ODN. TADM is immunomodulatory also in vivo and decreases the IgE levels and increases the IFN-gamma responses in a murine model. These results suggest that TADM may be a promising candidate for novel adjuvants in immunotherapy. (C) 2014 SEICAP. Published by Elsevier Espana, S.L.U. All rights reserved.